Good
Mostly Aligned
Patient Risk:
Low
Summary
Claims identify leucovorin (folinic acid) and brand/formulation equivalences. Provided label excerpts discuss leucovorin/folinic acid as the active moiety but do not confirm specific US brand names (e.g., Wellcovorin, Leucovorin Calcium, Fusilev) or manufacturer listings; thus brand-name/identity claims are only partially supported.
Category Scores
Accurate Statements
Leucovorin is also called folinic acid.
Label sections provided state leucovorin/folinic acid together as the active concept (e.g., hypersensitivity/contraindication wording includes 'leucovorin (folinic acid)' and references 'folinic acid antagonists' in the clinical context).
Fusilev is a leucovorin calcium injection formulation.
Supported only at the level that the label provided is for leucovorin calcium injection (VYKOURA is 'leucovorin calcium' injection). The excerpt does not explicitly name Fusilev, but the formulation concept 'leucovorin calcium injection' matches the provided label drug description.
Unsupported Statements
In the US, a brand name for leucovorin is Leucovorin Calcium (various brand/manufacturer listings).
Provided label excerpts do not mention this specific brand name or manufacturer listings.
In the US, a brand name for leucovorin is Wellcovorin.
Provided label excerpts do not mention this specific brand name.
In the US, a brand name for leucovorin is Fusilev, which is leucovorin calcium for injection.
Provided label excerpts do not mention the brand name Fusilev; they only describe leucovorin calcium injection for VYKOURA.
Contradictions
Important Omissions
No dosing, administration, contraindications, warnings/precautions, interactions, adverse reactions, or population-specific safety information were provided in the AI claims, but these are not applicable to the specific brand-name/identity statements being evaluated.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The claims are identity/brand-name related. The only fully supported identity is the synonym 'leucovorin' and 'folinic acid.' Brand-name mapping statements are unsupported by the provided excerpts but are unlikely to introduce safety-relevant dosing errors within the context of these statements alone.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Brand-name equivalence claims (Leucovorin Calcium, Wellcovorin, Fusilev) are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to label-supported synonyms (leucovorin/folinic acid) and label-supported formulation description ('leucovorin calcium injection') without asserting specific US brand names unless explicitly cited in the provided prescribing information.